Successful use of Orthoclone OKT 3 for steroid-resistant acute rejection in pediatric renal allograft recipients.
Use of Orthoclone OKT 3 for the treatment of steroid-resistant acute rejection in kidney transplant recipients is well described in the literature. Our experience with the use of OKT 3 in 16 pediatric kidney transplant recipients supports the use of this therapy in the pediatric population by reporting efficacy and lack of major complications. Monitoring of OKT 3 antibodies is recommended because of potential need to reuse OKT 3 in subsequent transplants. In addition, techniques of improving medical compliance, particularly in the adolescent population, is an area identified as needing further study. The combination of improving rejection therapies and specific nursing interventions in preparing children and their families in the use of OKT 3 as well as in enhancing compliance will improve the outlook of pediatric transplant recipients.
Palmer
J
J
Slook
P
P
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D016903:Drug Monitoring; D005260:Female; D006084:Graft Rejection / Q000187:drug effects*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000451:nursing / Q000523:psychology; D008297:Male; D016853:Muromonab-CD3 / Q000008:administration & dosage / Q000627:therapeutic use*; D010347:Patient Care Planning; D010349:Patient Compliance
D016853:Muromonab-CD3